Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action.

Metabolomic profiling 

Twenty marker metabolites contributing to the complete separation between post-treatment and pre-treatment patients were identified, with myo-inositol, uric acid and tryptophan showing the maximum combined classification performance. 

Schizophrenia
Enhanced by Zemanta

No comments: